Outlook Therapeutics(US:OTLK) Globenewswire·2026-02-19 14:00Core Viewpoint - Outlook Therapeutics, Inc. has entered into an exclusive commercial distribution agreement with Mediconsult AG for the sale and distribution of LYTENAVA™ (bevacizumab gamma) in Switzerland, aiming to enhance access to this treatment for retinal diseases in the European market [1][2][3] Company Overview - Outlook Therapeutics is a biopharmaceutical company focused on developing and commercializing ONS-5010/LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) to improve the standard of care for retinal diseases [10] - Mediconsult AG is a leading full-service partner for ophthalmic professionals in Switzerland, with over 35 years of experience in the ophthalmology market [9] Agreement Details - Mediconsult will have exclusive rights to market, import, distribute, and commercialize LYTENAVA™ in Switzerland, while also handling regulatory activities including seeking and maintaining Marketing Authorization [2][3] - Outlook Therapeutics will retain responsibility for manufacturing, product supply, and intellectual property maintenance [2] Market Potential - Switzerland is identified as an important European market for LYTENAVA™, with the product expected to launch in 2027, pending receipt of Marketing Authorization [4][8] - The partnership is part of a broader strategy to expand access to LYTENAVA™ across Europe while maintaining control over manufacturing and product quality [3] Product Information - LYTENAVA™ is an ophthalmic formulation of bevacizumab produced in the United States for the treatment of wet age-related macular degeneration (AMD) [5] - It has received centralized Marketing Authorization from the European Commission and the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK for treating wet AMD [5][10]